How to Value a Medical Spa Chain in 2026

Medical spas have been the darling of healthcare private equity for the last five years, and for good reason. The aesthetics market is growing 12-15% annually, margins are strong, and the recurring nature of injectables creates predictable revenue. But I've watched too many medspa owners walk into negotiations thinking their chain is worth more than it is — or worse, accept an offer that dramatically undervalues what they've built.

Valuing a multi-location medspa is fundamentally different from valuing a single-provider practice. The economics shift, the buyer pool changes, and the metrics that matter are not what most owners expect. Here's how it actually works.

Why Medspa Multiples Are So Wide

Multi-location medspa chains trade at 8-14x EBITDA, which is a massive range. A 3-location chain doing $1.5M EBITDA could be worth $12M or $21M depending on how it's structured. That gap comes down to a handful of factors that sophisticated buyers obsess over.

At the low end (8-10x), you're looking at chains where the founder is the medical director and primary injector, revenue is heavily dependent on a few star providers, and there's minimal infrastructure beyond the locations themselves. These are really just co-located solo practices with shared branding.

At the high end (12-14x), the chain has a scalable management layer, a training program for new injectors, strong SOPs across locations, and meaningful membership or subscription revenue. These are platforms, and PE firms pay platform prices for them.

Injector Retention Is the Valuation Lever Most Owners Miss

In every medspa transaction I've worked on, the first question from the buy side is always the same: "What happens to revenue if the lead injectors leave?" It's not a hypothetical. Injector turnover in aesthetics runs 25-35% annually at the industry level, and when a popular injector leaves, they take 40-60% of their personal book with them.

If your top injector generates 35% of total revenue across the chain and has no non-compete or has a weak one, a buyer is going to haircut your EBITDA by that risk. I've seen it knock 2-3 turns off the multiple.

What smart operators do: they build the brand bigger than any one provider. Patients book "a Botox appointment at [Brand Name]," not "an appointment with Sarah." They cross-train injectors so patients see different providers. They use enforceable non-competes (where state law permits) and retention bonuses tied to the transaction. A chain where no single injector represents more than 15% of revenue gets a materially better multiple.

Membership Revenue Changes the Math

The single most impactful thing a medspa chain can do before going to market is build membership revenue. Buyers — especially PE-backed platforms like Skin Laundry, Ever/Body, or the newer roll-ups — assign a premium to recurring revenue streams that would make a SaaS investor blush.

A typical medspa membership program charges $150-$300/month and includes a set number of units of neurotoxin, a monthly facial or peel, and discounts on additional services. The economics are powerful: members visit 2-3x more frequently than non-members, spend 40-60% more annually, and have retention rates above 80% at well-run locations.

Here's what I tell owners: if membership revenue is below 20% of total revenue, you're leaving money on the table at exit. Chains where 30-40% of revenue comes from memberships consistently trade at the top of the range. The math is simple — a buyer paying 12x EBITDA can underwrite membership revenue at higher confidence than walk-in injectable appointments, so they're willing to pay more for it.

Marketing Efficiency Tells Buyers Everything

Every medspa spends heavily on marketing — Instagram, Google Ads, influencer partnerships, Groupon (unfortunately). Buyers don't care how much you spend. They care about your customer acquisition cost (CAC) and what percentage of revenue goes to marketing.

Industry benchmarks for healthy medspas: marketing spend at 10-15% of revenue, new patient CAC of $150-$250, and a lifetime value to CAC ratio above 5:1. If you're spending 20%+ of revenue on marketing to maintain growth, a buyer sees a business that can't sustain itself without constant paid acquisition. That's a red flag.

The medspas that command top multiples have strong organic channels: a referral program that actually works, genuine social media presence (not just paid posts), and a reputation that drives walk-ins. One chain I advised had 45% of new patients from referrals and organic search — they got 13x EBITDA because the buyer knew that revenue base was durable.

Multi-State Compliance Is a Deal Killer or a Moat

Medical spas operate in one of the most fragmented regulatory environments in healthcare. Every state has different rules about medical director oversight, who can inject what, scope of practice for nurse practitioners and PAs, and how the management company can interact with the medical practice. Some states (like California and Texas) have aggressive medical board enforcement around the corporate practice of medicine.

I've seen deals fall apart in diligence because a multi-state chain had a management services organization (MSO) structure that worked in Florida but violated corporate practice of medicine rules in their New York locations. The buyer's healthcare attorneys flagged it, and unwinding the structure was going to cost $500K+ in legal fees and 6 months of delays.

On the flip side, a chain that has already solved multi-state compliance — with proper MSO/PC structures, state-specific medical director agreements, and clean regulatory history — has a genuine moat. A buyer acquiring a compliant 5-state operation saves 12-18 months of buildout time versus doing it themselves. That's worth a premium.

What Buyers Actually Underwrite

When a PE firm or strategic buyer models a medspa chain acquisition, they're building a detailed financial model around these specific metrics:

• Revenue per square foot: $600-$1,000/sq ft annually for top-performing locations. Below $400 signals underutilization.
• Revenue per treatment room: $250K-$400K annually. This tells them about capacity utilization and expansion potential.
• Same-store sales growth: 8-15% is healthy in aesthetics. Flat or declining same-store sales, even if total revenue is growing via new locations, is a yellow flag.
• EBITDA margin: 20-30% for well-run chains. Below 15% and buyers wonder about pricing power or cost control.
• Provider productivity: $400K-$600K in revenue per full-time injector. Significantly below that suggests underperformance.

The Medical Director Question

Every medspa needs a medical director, and how that relationship is structured matters enormously at sale. If the owner is the medical director, you have the same owner-dependency problem that plagues dental practices. The buyer needs to find a replacement, which costs $150K-$300K annually depending on the market, and that comes straight off the EBITDA they're willing to pay a multiple on.

If you already have a contracted medical director who isn't the selling owner, that's a significant positive. The buyer inherits a turnkey compliance structure. Make sure the medical director agreement is assignable or that the physician is willing to enter a new agreement with the buyer — get this sorted before going to market.

Preparing a Medspa Chain for Sale

If you're 12-24 months from exit, here's where to focus your energy:

Push membership revenue above 25%. Launch or expand your membership program aggressively. Every incremental membership dollar is worth more at exit than the same dollar from walk-in services.

Distribute revenue across providers. If any single injector does more than 20% of chain revenue, start shifting patients and marketing spend. This is painful but essential.

Clean up compliance.Hire a healthcare attorney to audit your MSO/PC structure in every state. Fix issues now, not during diligence when they'll cost you 10x more in deal leverage.

Invest in systems. A chain running on spreadsheets and a patchwork of software signals operational immaturity. Unified EMR, centralized scheduling, standardized treatment protocols, and real-time financial dashboards across locations — these are what make a chain look like a platform.

Document your unit economics.Buyers want to see a proven playbook for opening new locations. What's the buildout cost? Time to breakeven? Ramp curve? If you can show that your last three locations each hit $100K/month within 9 months of opening, you've just justified the top of the multiple range.

The Bottom Line

Multi-location medspa chains are in high demand, but not all chains are valued equally. The difference between 8x and 14x EBITDA comes down to provable recurring revenue, injector independence from any single provider, regulatory compliance across jurisdictions, and a management layer that can operate and grow without the founder. Build those elements, and you'll command multiples that reflect the true value of what you've created.